Asset profile
Tadalafil · Adcirca
Small molecule
Evidence outlook · lead readout
NCT01824290 · Hypertension, Pulmonary
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found. A further registrational readout is expected around 2027-01-31.
NCT01824290: This trial was randomized, double-blind, and placebo-controlled, and it measured a recognized functional outcome (walking distance) in children with pulmonary arterial hypertension. However, although tadalafil-treated children walked further on average, the difference from placebo did not reach statistical significance, so the trial does not show a clear benefit despite its otherwise rigorous design.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
64 competitors in this universe: 3 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 8 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Tadalafil (Adcirca): this drug | Phase 3 | Small molecule | PDE5 | ||
| Sildenafil (Revatio) | Phase 3 | Small molecule | PDE5 | ||
| Udenafil (Zydena) | Phase 3 | Small molecule | PDE5 | ||
| RTN-001 | Phase 2 | Small molecule | PDE5 | ||
| AR1001 | Phase 3 | Small molecule | PDE5 | ||
| Aprocitentan (Tryvio) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Bosentan (Tracleer) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | ||
| Epoprostenol (Flolan) | Approved | Small molecule | IP receptor (prostacyclin pathway) | ||
| Nitric Oxide (INOmax) | Approved | Gas (inhaled) | Nitric oxide | ||
| Sacubitril / Valsartan (Entresto) | Approved | Small molecule | Neprilysin + Angiotensin II receptor (dual) | ||
| Treprostinil (Orenitram / Remodulin / Tyvaso) | Approved | Small molecule | IP receptor (prostacyclin pathway) | ||
| Treprostinil (Yutrepia, Liquidia) | Approved | Small molecule | IP receptor (prostacyclin pathway) | ||
| AD-209 | Phase 3 | Small molecule | Angiotensin II type 1 receptor / L-type calcium channel / Na-Cl cotransporter | ||
| AGSAVI | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / Thiazide-like diuretic | ||
| AJU-C52 | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / Thiazide-like diuretic |
…and 49 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(18 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (4)
November 2026 (3)
What to watch
What to watch
What to watch
December 2026 (1)
What to watch
2027 (7)
January 2027 (2)
What to watch
What to watch
February 2027 (1)
What to watch
June 2027 (1)
What to watch
September 2027 (1)
What to watch
October 2027 (1)
What to watch
November 2027 (1)
What to watch
2028 (5)
March 2028 (1)
What to watch
May 2028 (1)
What to watch
August 2028 (1)
What to watch
September 2028 (1)
What to watch
December 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.